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Summary
Methods For the patch test, commercially available test product and its vehicle were applied occluded for 12-days
to photoaged forearm skin (n = 10) prior to biopsy and immunohistochemical assessment of ﬁbrillin-1; all-trans
retinoic acid (RA) was used as a positive control. Sixty photoaged subjects were recruited to the RCT (test pro-
duct, n = 30 vs. vehicle, n = 30; once daily for 6-months; face & hands) with clinical assessments performed at
recruitment and following 1-, 3- & 6-months of use. Twenty-eight subjects had skin biopsies (dorsal wrist) at
baseline and at 6 months of treatment for immunohistochemical assessment of ﬁbrillin-1 (test product, n = 15;
vehicle, n = 13). All subjects received test product for a further 6-months. Final clinical assessments were per-
formed at the end of this open period; 27 subjects received test product for 12-months.
Results In the 12-day patch test assay, we observed signiﬁcant immunohistological deposition of ﬁbrillin-1 in skin
treated by test product and RA as compared to untreated baseline (P =0 Æ005 and 0Æ015 respectively). In the clini-
cal RCT, at 6 months, compared to baseline assessment, 43% of subjects on test product had an improvement in
facial wrinkles (P =0 Æ013), whereas only 22% of subjects using vehicle had clinical improvement (P = ns).
Between group comparison of test product and vehicle was non-signiﬁcant (P =0 Æ10). After 12 months, there
was a signiﬁcant beneﬁt of test product over that projected for vehicle (70% vs. 33% of subjects improving; com-
bined Wilcoxon rank tests, P =0 Æ026). There was signiﬁcant deposition of ﬁbrillin-1 in skin treated for 6 months
with test product (mean ± SE; vehicle, 1Æ84 ± 0Æ23; test product, 2Æ57 ± 0Æ19; P =0 Æ019).
Conclusion An over-the-counter cosmetic ‘anti-ageing’ product demonstrated clear beneﬁt over vehicle in ﬁbrillin-1
deposition over a 6-month trial period. There was a corresponding but non-signiﬁcant trend towards clinical
improvement in facial wrinkles. Clinical improvements in the treated group were increased after a further
6-months of use. This study demonstrates that a cosmetic may improve the appearance of wrinkles and further
supports the use of ﬁbrillin-1 as a robust biomarker for repair of photoaged dermis.
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Summary
Background Very few over-the-counter cosmetic ‘anti-ageing’ products have been
subjected to a rigorous double-blind, vehicle-controlled trial of efﬁcacy. Previ-
ously we have shown that application of a cosmetic ‘anti-ageing’ product to
photoaged skin under occlusion for 12 days can stimulate the deposition of
ﬁbrillin-1. This observation infers potential to repair and perhaps clinically
improve photoaged skin.
Objective We examined another similar over-the-counter cosmetic ‘anti-ageing’
product using both the patch test assay and a 6-month double-blind, randomized
controlled trial (RCT), with a further 6-month open phase to assess clinical efﬁ-
cacy in photoaged skin.
Methods For the patch test, a commercially available test product and its vehicle
were applied occluded for 12 days to photoaged forearm skin (n = 10) prior to
biopsy and immunohistochemical assessment of ﬁbrillin-1; all-trans retinoic acid
(RA) was used as a positive control. Sixty photoaged subjects were recruited to
the RCT (test product, n = 30 vs. vehicle, n = 30; once daily for 6 months, face
and hands) with clinical assessments performed at recruitment and following 1,
3 and 6 months of use. Twenty-eight volunteers had skin biopsies (dorsal wrist)
at baseline and at 6 months treatment for immunohistochemical assessment of
ﬁbrillin-1 (test product, n = 15; vehicle, n = 13). All volunteers received the test
product for a further 6 months. Final clinical assessments were performed at the
end of this open period.
Results In the 12-day patch test assay, we observed signiﬁcant immuno-
histological deposition of ﬁbrillin-1 in skin treated with the test product and
RA compared with the untreated baseline (P =0 Æ005 and 0Æ015, respectively).
In the clinical RCT, at 6 months, the test product produced statistically
signiﬁcant improvement in facial wrinkles as compared to baseline assessment
(P =0 Æ013), whereas vehicle-treated skin was not signiﬁcantly improved
(P =0 Æ11). After 12 months, there was a signiﬁcant beneﬁt of the test
product over that projected for the vehicle (70% vs. 33% of subjects
improving; combined Wilcoxon rank tests, P =0 Æ026). There was signiﬁcant
deposition of ﬁbrillin-1 in skin treated for 6 months with the test product
[(mean ± SE) vehicle 1Æ84 ± 0Æ23; test product 2Æ57 ± 0Æ19; ANCOVA
P =0 Æ019).
Conclusions In a double-blind RCT, an over-the-counter cosmetic ‘anti-ageing’
product resulted in signiﬁcant clinical improvement in facial wrinkles, which was
associated with ﬁbrillin-1 deposition in treated skin. This study demonstrates that
a cosmetic product can produce signiﬁcant improvement in the appearance of
wrinkles and further supports the use of ﬁbrillin-1 as a robust biomarker for the
repair of photoaged dermis.
All tissues, regardless of body site, are subject to intrinsic age-
ing, the result of the passage of time. Few clinically apparent
changes occur in intrinsically aged skin until the individual is
over 70 years of age at which point ﬁne wrinkles become
apparent.
1 Skin, more than any other organ, is also subject
to environmental inﬂuences which can lead to extrinsic
ageing. One such environmental factor is chronic exposure to
sunlight which results in phenotypic changes termed photo-
ageing—inevitably a combination of intrinsic ageing and
photodamage. By comparison with intrinsic ageing, photoaged
skin is rough, dyspigmented and exhibits both ﬁne and deep
wrinkles.
2,3 Histological examination of intrinsically aged skin
reveals atrophy of the dermal extracellular matrix (ECM), with
reduced levels of collagen and elastin.
4 Photoaged skin has a
different ECM morphology with solar elastosis—the deposition
of dystrophic elastic ﬁbres in the dermis—being a prominent
histological feature.
5 Photoaged dermis contains signiﬁcantly
reduced levels of collagen types I and III,
6 fewer anchoring
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7
and loss of the ﬁbrillin-rich microﬁbrillar architecture in the
papillary dermis.
8 These remodelled ageing phenotypes are
thought in part to be due to increased cutaneous expression
of matrix metalloproteinases (MMPs).
9–11
Topical retinoids are used as the clinical, evidence-based ‘gold
standard’ for the treatment of photoaged skin.
12 Numerous
studies have shown the reparative effects of topical application
of all-trans retinoic acid (RA), which includes the partial restora-
tion of collagens I, III
13 and VII
14 and restoration of the ﬁbril-
lin-rich microﬁbrillar network.
15 These ECM changes, together
with reduced MMP expression may in part explain the clinical
improvement of photoaged skin produced by topical retin-
oids.
16–18 We showed previously, in a 12-day occluded patch
test assay, that a speciﬁc cosmetic ‘anti-ageing’ product also has
the ability to stimulate the accumulation of ﬁbrillin-1.
19
Although prescription retinoids can affect these signiﬁcant
clinical and histological changes in photoaged skin there is
scant evidence that any of the plethora of cosmetic ‘anti-
ageing’ products can produce similar effects. We ﬁrstly
examined whether another, similar cosmetic ‘anti-ageing’
product can induce accumulation of ﬁbrillin-1 in photoaged
skin using the patch test protocol. We then investigated the
same product in a rigorous double-blind, randomized
controlled trial (RCT) to ascertain whether or not its use
results in a clinically detectable beneﬁt.
Methods
Test products
A commercially available product provided by Alliance Boots
Ltd (No7 Protect & Perfect Intense Beauty Serum ; Alliance
Boots Ltd, Nottingham, UK) was investigated in these studies,
together with a vehicle formulation. The product is a water in
silicone emulsion with glycerine and other emollients and a
complex of ‘anti-ageing’ ingredients comprising natural
extracts and peptides: sodium ascorbyl phosphate, Panax ginseng,
Morus alba, Lupinus alba, tocopherol, palmitoyl oligopeptide,
palmitoyl tetrapeptide-7, Medicago sativa and retinyl palmitate.
The vehicle was of identical composition, but without the
complex of ‘anti-ageing’ ingredients.
In vivo patch test study
Ten healthy but photoaged volunteers were recruited (four
men, six women; age range 61–76 years) and subjected
to an extended 12-day patch test assay.
19 Test substances
(vehicle and test product 20 lL) were applied separately to the
extensor photoaged aspect of the forearm under standard 6-mm
diameter Finn chambers (Scanpore, Tuulsula, Finland). In add-
ition, an area was left untreated but was occluded to provide a
baseline control sample. Test products were applied to clean skin
on days 1, 4 and 8 of the assay. RA (0Æ025%; Retin-A
  cream;
Janssen-Cilag Ltd, Beerse, Belgium; 20 lL) was applied to an
untreated site on day 8 and left in situ for 4 days to avoid
potential complications of irritancy caused by extended occlu-
sion. On day 12, the Finn chambers were removed and 3-mm
punch biopsies were obtained under 1% lignocaine local
anaesthesia from each test site. Biopsied tissue was embedded
in optimal cutting temperature compound (Tissue-Tek
 ;M i l e s
Laboratories, Elkhart, IN, U.S.A.), snap frozen in liquid nitrogen
and stored at )70  C prior to immunohistochemical analyses.
The North Manchester Local Research Ethics Committee approved
the study and all subjects gave written, informed consent.
Slide preparation
Frozen sections were prepared at a thickness of 10 lm (OTF
cryostat; Bright Instruments Ltd, Cambridge, U.K.) and moun-
ted onto gelatin-coated slides prior to histological analysis.
Immunohistochemistry
Immunohistochemistry was performed as previously des-
cribed
19 to identify a panel of ECM molecules or remodelling
enzymes in frozen sections from the 12-day patch test assay
and from the RCT. Primary antibodies were applied overnight
at 4  C. These were: mouse antihuman ﬁbrillin-1 (clone
11C1.3; Neomarkers, Union City, CA, U.S.A.) diluted 1 : 100;
rat antihuman procollagen-1 (pCI) (clone M-58; Chemicon
International Inc., Temecula, CA, U.S.A.) diluted 1 : 1000; or
mouse antihuman MMP-1 (Oncogene Research Products, Bos-
ton, MA, U.S.A.) diluted 1 : 100. Negative controls were by
incubation of isotype sera at the appropriate concentration or
omission of the primary antibody. Sections were washed in
TBS prior to incubation with the appropriate biotinylated sec-
ondary antibody for 30 min. Antibody staining was visualized
using a well-characterized immunoperoxidase reaction (Vecta-
Stain
  Elite ABC system; Vector Laboratories, Burlingame, CA,
U.S.A.) utilizing Vector SG
  as chromogen. Following light
counterstaining with nuclear fast red, sections were serially
dehydrated and permanently mounted. Stained sections were
randomized, blinded and examined on a Nikon OPTIPHOT
microscope (Tokyo, Japan). The degree of immunostaining for
ﬁbrillin-1 and pCI was assessed as previously described.
8,15,19
In brief, a ﬁve-point semiquantitative scale was used where
0 = no staining and 4 = maximal staining within the experi-
ment. The numbers of epidermal keratinocytes positive for
MMP-1 were quantiﬁed per high-power ﬁeld (hpf; · 400).
Four sections (including control) were examined per subject,
per site, per treatment and the average score calculated.
Randomized controlled trial
Sixty healthy but photoaged volunteers were recruited to this
study (11 men, 49 women; age range 45–80 years). All test
products were supplied in identically packaged, coded con-
tainers so that the investigators and subjects were unaware as
to the treatment. Subjects were randomly allocated to self-
treatment with either the vehicle formulation or the test prod-
uct as described by a randomization programme (StatsDirect
  2009 Boots Company Plc • British Journal of Dermatology 2009 161, pp419–426
Clinical efﬁcacy of a cosmetic ‘anti-ageing’ product, R.E.B. Watson et al. 421Ltd, Altrincham, U.K.) and instructed on the use of their allot-
ted cream—daily evening application to the entire face and
dorsa of the hands, including the wrists and extensor forearm,
for 6 months. Clinical assessments of the skin of the face and
dorsal hands were performed for all participants at baseline
and following 1, 3 and 6 months of product use. The follow-
ing four parameters were assessed at each visit: ﬁne lines and
wrinkles, dyspigmentation, overall clinical grade of photoage-
ing and tactile roughness. The degree of ﬁne lines and wrin-
kles, dyspigmentation and the overall level of photoageing
were scored according to the well-characterized Grifﬁths
photonumeric scale for photoaged skin.
20 The scale ranges
from 0 to 8, where 0 represents no evidence of photoageing
and 8 represents the most severe photoageing. Pigment was
assessed on a similar 0–8 scale, where 0 denotes a uniform
coloration of the skin with absence of photoageing-related
colour change and 8 represents severe dyspigmentation. Like-
wise, tactile roughness was scored on the treated areas from 0
to 8, where 0 represents totally smooth skin with no rough
patches and 8 represents very roughened skin.
In addition, 28 subjects provided 3-mm skin biopsies from
the dorsal wrist at the beginning and end of the 6-month
study period (vehicle formulation, n = 13; test product,
n = 15). These biopsies were evaluated for the expression of
ﬁbrillin-1 in the papillary dermis, as previously described.
19
All the subjects were monitored for the occurrence of serious
adverse events up to, and including, 28 days after their
involvement with this study. The Salford and Trafford Local
Research Ethics Committee approved the study and all the sub-
jects gave written, informed consent.
Statistical analyses
In vivo patch test study
Differences in the amount of ﬁbrillin-1 immunostaining
produced by the vehicle and test product were assessed for
signiﬁcance using the repeated measures analysis of variance
(ANOVA). Results were considered signiﬁcant if P <0 Æ05 (95%
conﬁdence level) and were calculated using SPSS+ v 11.5 soft-
ware (SPSS Inc., Chicago, IL, U.S.A.).
Randomized controlled trial
Clinical assessment. Analysis of covariance (ANCOVA), using the
baseline as covariate, was used to assess the 6-month data.
Linear regression analysis was used to extrapolate the vehicle
response to 12 months, thus allowing direct comparison with
the test product, validity conﬁrmed by the Monte Carlo simu-
lation.
21 As all volunteers used the test product in the ﬁnal
6 months, the 12-month clinical assessment data were analy-
sed using a combination of Wilcoxon’s matched pairs signed
rank and rank sum tests, to give an overall P-value.
In-use biopsy samples. ANCOVA was performed, using the baseline
as covariate to assess changes in the deposition of ﬁbrillin-1 in
the papillary dermis, with signiﬁcance taken at the 95% conﬁ-
dence level (SAS 9.1; SAS Institute Inc., Cary, NC, U.S.A.).
Results
In vivo patch test study
RA (the clinical ‘gold standard’) produced a signiﬁcant deposi-
tion of ﬁbrillin-1 in the papillary dermis compared with that
observed at baseline (P =0 Æ015). Application of the vehicle,
following the 12-day patch test assay, produced little effect on
ﬁbrillin-1 deposition (P >0 Æ05). However, application of the
test product resulted in a signiﬁcant deposition of ﬁbrillin-1,
the accumulation being at a similar level to that observed
using RA (mean ± SE) (baseline 1Æ27 ± 0Æ11; vehicle formu-
lation 1Æ70 ± 0Æ17; test product 2Æ64 ± 0Æ22, P =0 Æ005; RA
2Æ51 ± 0Æ28, P =0 Æ015; Fig. 1e). As in previous studies,
15
treatment with RA had little effect on deposition of pCI or on
the expression of MMP-1 in the epidermis (Table 1).
Randomized controlled trial
Clinical assessment
At 6 months, the test product produced statistically signiﬁcant
improvement in facial wrinkles as compared to baseline assess-
ment (P =0 Æ013), whereas vehicle-treated skin was not sig-
niﬁcantly improved (P =0 Æ11). 43% of the subjects who had
received the test product showed an improvement in facial
wrinkles compared with the baseline assessment, whereas only
22% of the subjects receiving the vehicle showed improve-
ment compared with baseline (Fig. 2). Use of the test product
produced a clinically signiﬁcant improvement in facial wrin-
kles after 12 months of use, with a statistically signiﬁcant
between-groups beneﬁt of test product vs. the vehicle (test
product, 70% of subjects improving compared with vehicle,
33% improving; combined Wilcoxon rank tests, P =0 Æ026)
(Fig. 2). No beneﬁts of the test product were seen
for improvement in mottled dyspigmentation. Use of either
formulation produced an improvement in skin texture
over that recorded at baseline (vehicle, P =0 Æ001; test prod-
uct, P =0 Æ001), but the test formulation did not perform sig-
niﬁcantly better than the vehicle (data not shown; P =0 Æ72).
In-use biopsy samples
The test product produced a signiﬁcant accumulation of ﬁbril-
lin-1 in the papillary dermis of photoaged skin at 6 months
compared with the vehicle (mean ± SE) (vehicle formulation
1Æ84 ± 0Æ23; test product 2Æ57 ± 0Æ19; ANCOVA, P =0 Æ019;
Fig. 3).
Discussion
We show here, for the ﬁrst time, that a commercially avail-
able over-the-counter ‘anti-ageing’ product improves the
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This improvement is associated with restoration of ﬁbrillin-1,
the major component of ﬁbrillin-rich microﬁbrils, in product-
treated skin.
In these studies, we performed a double-blind RCT
to assess whether or not an over-the-counter cosmetic
‘anti-ageing’ product can produce clinically signiﬁcant
improvement in the appearance of photoaged facial skin.
The trial was executed to the highest standards, with study
creams coded and randomized at source, and with the
volunteers, investigators and independent statistician ‘blind’
to the coding until after study completion and initial data
analysis. We did not observe any beneﬁt of the vehicle or
test product on the appearance of mottled dyspigmentation
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Fig 1. Fibrillin-rich microﬁbrils are deposited in test product- and all-trans retinoic acid (RA)-treated human skin in a short-term patch test assay.
Representative photomicrographs showing ﬁbrillin-rich microﬁbrils (arrows) in photoaged extensor forearm following the extended 12-day
patch test protocol: (a) baseline; (b) vehicle; (c) test product. (d) The positive control (0Æ025% RA) was applied for 4 days to avoid harmful
side-effects. Original magniﬁcation · 400. (e) Quantiﬁcation of ﬁbrillin-rich microﬁbrils following the occluded patch test assay with vehicle, test
product or the positive control (RA), compared with the baseline. We identiﬁed signiﬁcantly more ﬁbrillin-rich microﬁbrils with both the test
product (**P =0 Æ005) and RA (*P =0 Æ015).
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clinical assessments (S.O., J.Y.B.) showed that subjects
treated with the vehicle formulation had improved skin
texture compared with that observed at their recruitment,
but did not exhibit any change in the appearance of their
facial wrinkles. Those treated with the test product showed
improvements in both skin texture (compared with their
baseline clinical assessment) and, more importantly, in the
appearance of facial wrinkles. This improvement in the
appearance of facial wrinkles became signiﬁcant only after
12 months of daily product use comparing between groups.
It is interesting to note, however, that when compared with
the baseline, the test product did lead to a noticeable clini-
cal improvement in facial wrinkles (P =0 Æ013) in 43% of
treated individuals after 6 months, compared with only 22%
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Fig 2. Application of the test product results in clinical improvement
in facial wrinkles. (a) Clinical assessment identiﬁed a signiﬁcant
improvement (P =0 Æ026) in wrinkle grade following treatment
with the test product compared with the vehicle at 12 months, as
ascertained by using a Monte Carlo simulation. Standardized
photographs of the face of a 56-year-old woman at (b) baseline and
(c) after 6 months’ application of the test product show an
improvement in periorbital ﬁne lines and wrinkles.
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Fig 3. Fibrillin-rich microﬁbrils were assessed by immunohisto-
chemistry at recruitment (baseline, a) and after treatment with either
vehicle (data not shown) or test product (b). (c) Signiﬁcant
deposition of ﬁbrillin-rich microﬁbrils was observed in the test
product-treated skin. *P =0 Æ019.
Table 1 Expression of extracellular matrix
(ECM) molecules in photoaged skin
following 12-day occlusion with a cosmetic
‘anti-ageing’ product
ECM component Baseline Vehicle Test product 0Æ05% RA
Fibrillin-1 1Æ27 ± 0Æ11 1Æ70 ± 0Æ17 2Æ64 ± 0Æ22** 2Æ51 ± 0Æ28*
pCI 2Æ65 ± 0Æ15 2Æ64 ± 0Æ15 2Æ70 ± 0Æ13 2Æ63 ± 0Æ21
MMP-1 (cells ⁄hpf) 115Æ8±7 Æ9 140Æ3±1 3 Æ6 127Æ2±1 4 Æ1 143Æ7±1 2 Æ5
RA, all-trans retinoic acid; pCI, procollagen-1; MMP, matrix metalloproteinase; hpf, high-
power ﬁeld. *P =0 Æ015; **P =0 Æ005.
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ﬁcant improvement in appearance (P =0 Æ11). In a compari-
son between groups, this improvement was not statistically
signiﬁcant but does indicate that larger clinical trials of cos-
metic products might be expected to show useful clinical
improvement after 6 months’ use. The data from this study
are indicative that cosmetic ‘anti-ageing’ products can result
in noticeable clinical improvement in facial wrinkles. To our
knowledge, this is the ﬁrst time such beneﬁts have been
reported for a commercially available cosmetic ‘anti-ageing’
product and paves the way for larger studies with more
statistical power.
In addition, we examined the distribution of a key bio-
marker of photoageing—loss of ﬁbrillin-1 in the papillary
dermis—in skin samples obtained during the RCT. Fibrillin-1
is the major glycoprotein component of ﬁbrillin-rich micro-
ﬁbrils (oxytalan ﬁbres). Skin treated with the test product
contained signiﬁcantly more ﬁbrillin-rich microﬁbrils in the
papillary dermis than either the baseline samples or those
treated with the vehicle (P =0 Æ019). Our previous research,
which demonstrated that an over-the-counter cosmetic
‘anti-ageing’ product can bring about increased ﬁbrillin-1
deposition in the papillary dermis, used a short-term, exagger-
ated-use patch test assay.
19 In the current study, we sought to
determine whether results obtained using such an experimen-
tal system were predictive of clinical improvement following
long-term use of such a product.
Consumers purchasing cosmetic skin care products—partic-
ularly those purporting ‘anti-ageing’ properties—are presented
with a broad choice of available products and only limited
data regarding their efﬁcacy. The situation is further compli-
cated for consumers by the use of trademarked proprietary
names for ingredients and the relative lack of published long-
term studies to demonstrate product performance. We previ-
ously sought to investigate if a cosmetic ‘anti-ageing’ product
can have a measurable effect on ﬁbrillin-1 and established that
histological improvement could be achieved in a short-term
exaggerated-use assay.
19 The results from that study were
indicative of some degree of structural change in the skin
following use of a cosmetic but provided no evidence for
actual clinical improvement. To address this question, the
current study compared the use of a commercially available
cosmetic ‘anti-ageing’ skincare serum to its vehicle and has
shown that such a product is capable of bringing about a clin-
ical improvement in the appearance of photoaged skin when
used for 12 months.
The difference in efﬁcacy between the vehicle and the test
product demonstrates that a correctly formulated skincare
product can deliver clinically relevant skin improvement,
above that delivered by the vehicle base. The studied product
contains the retinol ester, retinyl palmitate, together with nat-
ural plant extracts, peptides and lipopeptides and antioxidants.
Other authors have shown evidence for the role of many of
these cosmetic ingredients in protecting against mechanisms
that lead to dermal degradation, such as increased MMP activ-
ity
22 and stimulating repair of dermal components.
23–25 It
was our belief that a combination of ingredients with activi-
ties known to address the multiple changes which occur in
photoaged skin (degradation of collagen and elastin, the
appearance of surface wrinkling and textural changes) may be
beneﬁcial in a cosmetic product when used long term. Specif-
ically, the retinyl palmitate, palmitoyl peptides and Medicago
sativa extracts have been shown in vitro to lead to deposition
of collagen 1 in model skin systems and the extract of white
lupin has been shown to inhibit MMP-1 (S.P. Long, unpub-
lished data). In our previous study using the 12-day assay, a
similar product induced deposition of pCI as well as ﬁbrillin,
together with inhibition of MMPs.
19 These data suggest that
the long-term beneﬁts described here may be due to a com-
bination of actions. The product does not contain sunscreens,
so the visible skin improvements cannot be attributed to
photoprotection of the skin. Further work is underway to elu-
cidate the relative contributions of the individual ingredients.
The ﬁnding that a clinically relevant improvement in the
appearance of photoaged skin was demonstrated with long-term
use of a commercially available cosmetic ‘anti-ageing’ product
may cause some to question whether such effects are within the
deﬁnition of a cosmetic. Improvement in the appearance of
wrinkles is considered to be a cosmetic action, as the effect is
localized to the skin and is not concerned with treatment or cor-
rection of a disease condition. Several other authors report that
application of cosmetic products leads to changes in skin physi-
ology, including changes in barrier function,
26,27 stratum
corneum thickness
28 and lipidogenesis
29 and that cumulative
effects of cosmetic products are possible, a principle demon-
strated for skin moisturization
30 and recognized by regulatory
authorities.
31 When compared with the long-term clinical
effects of topical RA, it can be seen that the degree of improve-
ment offered by a cosmetic product is still markedly less than
that which is achievable with a prescribed medicine.
32–38
In conclusion, these studies provide evidence that use of an
over-the-counter cosmetic ‘anti-ageing’ product is able to
induce clinically identiﬁable improvement in the appearance
of facial wrinkles following long-term use. This improvement
is associated with deposition of ﬁbrillin-rich microﬁbrils in
the papillary dermis of treated skin. The study further supports
the use of ﬁbrillin-1 in a short-term assay as a biomarker for
assessing efﬁcacy of potential photoageing repair products.
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